SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
This Quarter Return
-11.49%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$186M
AUM Growth
+$186M
(-33%)
Cap. Flow
-$63.1M
Cap. Flow
% of AUM
-34.01%
Top 10 Holdings %
Top 10 Hldgs %
37.92%
Holding
70
New
7
Increased
10
Reduced
25
Closed
19
Top Buys
| 1 |
SPDR S&P Biotech ETF
XBI
|
$5.38M |
| 2 |
Danaher
DHR
|
$4.64M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$3.74M |
| 4 |
Smith & Nephew
SNN
|
$2.84M |
| 5 |
Elanco Animal Health
ELAN
|
$2.64M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$8.69M |
| 2 |
AET
Aetna Inc
AET
|
$7.1M |
| 3 |
Align Technology
ALGN
|
$6.85M |
| 4 |
CELG
Celgene Corp
CELG
|
$4.48M |
| 5 |
Quest Diagnostics
DGX
|
$4.32M |
Sector Composition
| 1 | Healthcare | 90.94% |
| 2 | Energy | 2.02% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Molina Healthcare
MOH
$9.8B
| $3.49M | 1.88% |
30,000
-20,000
| -40% | -$2.32M |
|
27
Centene
CNC
$14.3B
| $3.4M | 1.83% |
29,450
-15,550
| -35% | -$1.79M |
|
28
Thermo Fisher Scientific
TMO
$186B
| $3.36M | 1.81% |
15,000
-5,000
| -25% | -$1.12M |
|
29
Agilent Technologies
A
$35.7B
| $3.18M | 1.71% |
47,148
+32,148
| +214% | +$2.17M |
|
30
Bio-Rad Laboratories Class A
BIO
$8.06B
| $2.9M | 1.56% |
12,500
-7,500
| -38% | -$1.74M |
|
31
Teva Pharmaceuticals
TEVA
$21.1B
| $2.85M | 1.54% |
185,000
-15,000
| -8% | -$231K |
|
|
32
Smith & Nephew
SNN
$16.3B
| $2.84M | 1.53% |
+76,000
| New | +$2.84M |
|
33
Bausch Health
BHC
$2.74B
| $2.77M | 1.49% |
150,000
-20,000
| -12% | -$369K |
|
|
34
Elanco Animal Health
ELAN
$9.12B
| $2.64M | 1.42% |
+83,637
| New | +$2.64M |
|
|
AMED
35
DELISTED
Amedisys
AMED
| $2.34M | 1.26% |
+20,000
| New | +$2.34M |
|
36
Incyte
INCY
$16.5B
| $2.23M | 1.2% |
35,000
-5,000
| -13% | -$318K |
|
37
Sarepta Therapeutics
SRPT
$1.78B
| $2.18M | 1.18% |
20,000
-5,000
| -20% | -$546K |
|
38
Zimmer Biomet
ZBH
$21B
| $2.07M | 1.12% |
20,000
-20,000
| -50% | -$2.07M |
|
39
McKesson
MCK
$85.4B
| $1.66M | 0.89% |
15,000
-7,500
| -33% | -$829K |
|
40
Viatris
VTRS
$12.3B
| $1.54M | 0.83% |
56,186
-38,814
| -41% | -$1.06M |
|
|
LOXO
41
DELISTED
Loxo Oncology, Inc
LOXO
| $1.4M | 0.76% |
10,000
-5,000
| -33% | -$701K |
|
|
SAGE
42
DELISTED
Sage Therapeutics
SAGE
| $958K | 0.52% |
10,000
| – | – |
|
43
DexCom
DXCM
$29.5B
| $899K | 0.48% |
7,500
-12,500
| -63% | -$1.5M |
|
44
Cencora
COR
$56.5B
| $744K | 0.4% |
10,000
-27,500
| -73% | -$2.05M |
|
45
Agios Pharmaceuticals
AGIO
$2.19B
| $692K | 0.37% |
15,000
-5,000
| -25% | -$231K |
|
46
Haemonetics
HAE
$2.63B
| $500K | 0.27% |
5,000
-15,000
| -75% | -$1.5M |
|
|
GWPH
47
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $487K | 0.26% |
5,000
-22,500
| -82% | -$2.19M |
|
48
Moderna
MRNA
$9.37B
| $382K | 0.21% |
+25,000
| New | +$382K |
|
|
49
Align Technology
ALGN
$10.3B
| – | – |
-17,500
| Closed | -$6.85M |
|
|
BLUE
50
DELISTED
bluebird bio
BLUE
| – | – |
-7,500
| Closed | -$1.1M |
|